BLADDER CHONDROSARCOMA IN A MALE: A RARE CASE REPORT

Muhammad Husni Tamrin1, Wahjoe Djatisoesanto2

1 Resident of Urology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
2 Staff at the Department of Urology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

ABSTRACT

Chondrosarcoma is a rare variant of bladder tumor and one of the rare types of soft tissue sarcoma. This case happened on a 36-year-old male who complained of lumps in his lower abdomen, accompanied by difficulties in passing urine and painful urination, without hematuria. We performed TURBT and histopathological examination showed low-grade chondrosarcoma. The patient was diagnosed with low-grade bladder chondrosarcoma. The patient was treated for chemotherapy and radiotherapy. However, after undergoing one cycle of chemotherapy, the patient refused to continue the therapy.

Keywords: Sarcoma; chondrosarcoma; bladder tumors; disease

ABSTRAK


Kata kunci: Sarcoma; khondrosarkoma; tumor buli; disease

Correspondence: Wahjoe Djatisoesanto, Department of Urology, Dr. Soetomo General Academic Hospital, Surabaya, East Java 60286. Email: wdjatisoesanto@gmail.com
INTRODUCTION

Chondrosarcoma is a type of soft tissue sarcoma that rarely occurs (Kim et al 2011). It is responsible for no more than 0.5% of all bladder malignancy cases (Sule et al 2015). Bladder chondrosarcoma is a rare extraskeletal chondrosarcoma (Cho et al 2016).

A pelvic-abdominal magnetic resonance imaging (MRI) examination is able to describe bladder chondrosarcomas with clarity compared to a pelvic-abdominal CT scan (He et al 2016) MRI could show tumor invasion of the pelvic-abdominal organs and internal view of the tumor (Casali & Blay 2010).

The principle of bladder chondrosarcoma therapy is surgery, namely transurethral resection of bladder tumor (TURBT) (Richterstetter et al 2012, Miyake et al 2021). The TURBT aims to eradicate the tumor, biopsy, radical cystectomy, multidisciplinary treatment based on the histopathological subtypes, and chemoradiation (Sule et al 2015). We reported a case of low-grade bladder chondrosarcoma.

CASE PRESENTATION

A 36-year-old male patient came to the Urology Clinic with a chief complaint of a lump in the lower abdomen for the last 1.5 years. The lump was initially felt as large as a marble and it became gradually bigger to the size of a pear. The complaint was accompanied by pain, nausea, and weight loss without fever in the last six months. There were complaints of painful, dribbling urination, without blood in the urine. The patient also complained of defecating difficulties.

Based on the physical examination findings, there was a suprapubic solid mass, ±20x15x10 cm in size. It had a hard consistency with tenderness, and it fixed to the surrounding tissue. Digital rectal examination indicated normal anal sphincter tone, bulbocavernous reflex, and smooth anal mucosal layer. However, there was an extraluminal mass at the eleven to one o'clock position. The prostate was within normal limits.

The laboratory examination found hemoglobin: 8.6 g/dL, leukocytes: 8.430/uL, and platelet: 330.000/uL. Renal function test showed abnormal results of blood urea nitrogen (BUN) (121 mg/dL) and serum creatinine (21.56 mg/dL). The urinalysis obtained a pH of 6, leucocytes: 25-50/field of view, and erythrocytes: 50-100/field of view. The patient's serum electrolyte analysis showed hyperkalemia condition with a potassium level of 5.6 mmol/L.

The initial radiological examination of the patient was ultrasonography (USG) (Figure 1). It showed a solid cystic mass with distinct border, and intraluminal vascularization (+) in the pelvic cavity measuring at 16x13x19 cm. Bilateral moderate hydronephrosis was also obtained. Other abdominal organs were normal.
Figure 1. Ultrasonography (USG): Cystic solid mass with distinct border, and intrallesional vascularization (+) in the pelvic cavity measuring at 16x13x19 cm. Bilateral moderate hydronephrosis was also shown. Other abdominal organs were normal.

The magnetic resonance imaging (MRI) of the pelvic-abdomen region without contrast (Figure 2), showed suspicious mass in the seminal vesicles, cystic with septa, with solid components, partially indistinct borders, lobed edges, measuring at ±16x10.8x10.5 cm. The mass was attached to the inferior side of bladder, with partially indistinct borders, showed an impression of infiltration into the bladder, pressing the right and left ureters causing bilateral moderate hydronephrosis and hydroureter.

Figure 2. Magnetic resonance imaging (MRI) of the pelvic-abdomen region without contrast.
The patient was initially diagnosed with a pelvic cavity mass towards a suspicion of seminal vesicle tumor, with bilateral moderate hydronephrosis and hydroureter. The patient underwent cystoscopy, bladder, seminal vesicle biopsy, trans-rectal prostate biopsy, and right-left percutaneous nephrostomy (PNS). At the time of cystoscopy, there was a papillary mass, exophytic from the bladder neck which occupied the entire bladder. The mass was fragile, prone to bleeding, and the ureteral opening was difficult to evaluate (Figure 3). Afterwards, a mass biopsy was performed in the bladder.

Figure 3. Cystoscopy: visible mass from the neck of the bladder which occupies the entire bladder

The patient then underwent a right-left percutaneous nephrostomy (PNS) with 20 cc of urine from the right-left PNS, and the urine from the left PNS was 15 cc, with clear-yellow color. USG examination (Figure 4) showed right mild hydronephrosis and percutaneous nephrostomy (PNS) with nasogastric tube (NGT) in the pelvic-calyx-system (PCS).

Figure 4. Ultrasonography (USG) indicating right-left mild hydronephrosis, and right-left percutaneous nephrostomy (PNS) with nasogastric tube (NGT) in the pelvic-calyx-system (PCS)

The anatomical pathology results of the biopsy confirmed the infiltrating tumor in bladder and seminal vesicles as low-grade chondrosarcoma (Figure 5). Based on the discussion of the urologist, radiologist, and anatomical pathologist, the tumor in this case was originated from the bladder, and diagnosed as bladder chondrosarcoma. This decision was also made based on the literature study that reported several bladder chondrosarcoma cases, even though it was a rare case.
Figure 5. Histopathological results of the bladder showing transitional epithelial lining tissue and fragments of neoplastic chondroid cells with large pleiomorphic hyperchromatic nuclei and clear cytoplasm, suggesting a low grade chondrosarcoma (200x magnification)

We planned chemotherapy and radiation therapy for the patient. After one cycle of chemotherapy, the therapy was discontinued because the patient dropped out from the treatment. The patient returned after 1.5 years with recurrent complaints of dysuria, hematuria, and pain sensation in the lower abdominal area. The patient did not want to continue the chemotherapy or radiotherapy, and decided to do palliative therapy instead.

DISCUSSION

Bladder chondrosarcoma is a soft tissue tumor or sarcoma which is very rare in the bladder (Ikemoto et al 2004, Zulfariska et al 2020). The most common bladder sarcoma is leiomyosarcoma (Zieschang et al 2019), and comprising about 60-73% of all cases. Rhabdomyosarcoma and angiosarcoma are other types of sarcomas that can be found on the bladder, comprising about 20% and 15% of all cases, respectively (Gupta et al 2015).

There are only 6 reported cases of bladder chondrosarcoma in the British medical literature (Sule et al 2015). Of the cases reported, five cases complained of dysuria, urinary, frequency, and hematuria. Complaints of hematuria are found in ± 85% of malignancies in the bladder, either gross or microscopic hematuria (American Cancer Society 2014). Chemotherapy agent for bladder chondrosarcoma patients according to the recommendation is doxorubicin and cisplatin accompanied by 6 cycles of GCSF (Granulocyte colony stimulating factors) prophylaxis, with a time span between 2 cycles for 21 days (von Mehren et al 2016).

The doxorubicin regimen was administered at a dose of 25 mg/m2 body surface area (BSA), intravenously in 100mL of 0.9% NaCl solution for 4 hours on day 1, 2, and 3 before rehydration. Cisplatin is given at a dose of 25 mg/m2 BSA, administered intravenously in 1000 ml of 0.9% NaCl solution for 8 hours on day 1 and 2 after rehydration. On the 4th day, it can be given GCSF prophylaxis (Granulocyte colony stimulating factors), such as leukogen or filgrastim (Petsko 2011).

Local therapy using radiotherapy can be given before and after surgery (Baskar et al 2012), and it depended on the clinical condition of the patient, where it can also determine his radiotherapy techniques (Yoon et al 2021). Radiotherapy doses between 45-50 Gy in 25 to 28 times of administration, with integrated doses simultaneously up to a total dose of 57.5 Gy in 25 times of administrations. The limits of radiotherapy in the tumor is determined by the surgeon and the radiation oncologist (Petsko 2011).

CONCLUSION

Multimodal approaches including chemotherapy, surgery, and or radiotherapy are the principle of bladder chondrosarcoma. The intensity and timing of treatment should be planned according to each patient’s condition.

REFERENCES

randomized control trial (the FLEBER study). Trials 22, 1-10.